At forethought access, we are passionate about identifying solutions that help patients to access new treatments for orphan and genetic diseases. Thanks to breakthrough innovations in understanding and correcting genetic defects, we are living in an era of great hope for many patients affected by genetic – and often orphan – disorders. In addition to the dramatic improvements in the lives of patients and their families, new treatments also have the potential to profoundly change the way drugs – and in particular orphan drugs – are reimbursed. The broad knowledge of national and local payer decision making processes and their drivers, possession of dedicated tools to evaluate early–stage market access potential and prompt access to a large network of experts make our services particularly useful for companies active in the orphan and genetic disease areas.